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Abstract 
Human subjects research has the potential to produce information beyond the aims of 
the research study. This information may, nevertheless, have health or reproductive 
significance for the research participant. With the development of sophisticated 
technologies, these occurrences, known as incidental findings (IFs), are becoming 
increasingly common. As yet, however, there is no consensus on how IFs in human 
subjects research should be managed. This paper examines the current law and 
guidelines relating to human subjects research, and in doing so determines that 
research participants are inadequately informed about IFs. Consequently, their ability 
to make an informed choice about and provide informed consent to research procedures 
is compromised. After addressing the ethical and practical issues most salient to IFs, a 
framework for their management is developed. The framework sets out the information 
that should be discussed with research participants during the informed consent 
process. Recommendations for how this framework should be implemented are then 
made. The paper concludes that guidelines establishing minimum standards for 
communicating the possibility and presence of IFs are urgently required so that the 
rights of research participants are sufficiently protected. 
 
Word length 
The text of this paper (excluding abstract, table of contents, footnotes and bibliography) 
comprises approximately 15,007 words. 
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I Introduction 
At first glance, the problem of incidental findings (IFs) may seem incidental. For so 
long, our attention has been devoted to the development of human subjects research.
1
 It 
may, therefore, be assumed that research teams know how to address any clinically 
relevant information generated unexpectedly from such research.
2
 The truth, however, is 
that IFs are far from inconsequential and, as yet, there is no consensus as to their 
management in human subjects research.
3
 Although IFs are not a new phenomenon, the 
development of sophisticated technologies used to generate images, scans, and data 
means that the likelihood of such discoveries has increased dramatically.
4
 In light of 
this, it is more important than ever to develop a coherent framework for the management 
of IFs in research. 
The focus of this paper is on IFs discovered in the course of research, and not clinical 
care. A significant literature already exists addressing IFs in clinical care. Attention to 
IFs in research, on the other hand, is at an earlier stage and is comparatively more 
contentious.
5
 
This paper starts with an overview of the issue of IFs and the context in which they 
arise. Part III examines the current framework for addressing IFs in human subjects 
research both in New Zealand and internationally. Part IV addresses both the ethical and 
practical issues salient to IFs, before Part V, in consideration of these issues, puts 
forward a proposal for the management of IFs in New Zealand. This final part also 
examines the ways in which this proposal should be implemented. The paper concludes 
that guidelines establishing minimum standards for communicating the possibility and 
presence of IFs in research are required. How such regulations should look is, 
nonetheless, the subject of an intense debate and, at present, is highly controversial.
6
  
                                                
1  Susan M Wolf “Introduction: The Challenge of Incidental Findings” (2008) 36 J L M & E 216 at 
216. 
2
 At 216. 
3
  At 216. 
4
  Ellen Wright Clayton “Incidental Findings in Genetics Research Using Archived DNA” (2008) 
36 J L M & E 286 at 287. 
5
  Susan M Wolf and others “Managing Incidental Findings in Human Subjects Research: Analysis 
and Recommendations” (2008) 36 J L M & E 219 at 219. 
6
  Bert Heinrichs “A New Challenge for Research Ethics: Incidental Findings in Neuroimaging” 
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II Incidental Findings 
An IF may be defined as “a finding that has potential health or reproductive significance, 
unknown to the participant, which is discovered in the course of conducting research, 
but is unrelated to the purpose and beyond the aims of the study”.
7
 Examples of common 
IFs include one on a genomic microarray suggesting a genetic variant of potential 
clinical importance beyond the variants directly under study, an IF of misattributed 
paternity in a genetic family study, an unexpected mass or aneurysm identified in the 
course of an magnetic resonance imaging (MRI) scan of the brain, and an unexpected 
mass at the base of the lung discovered in a CT colonoscopy.
8
 
As research becomes increasingly large-scale, using powerful technologies, the problem 
of incidental findings is becoming more serious.
9
 Although virtually any study involving 
a human subject could reveal an IF, in recent years, researchers in imaging and genetics, 
in particular, have turned their attention to this issue.
10
 In the past, most genetics studies 
examined a limited number of genes or sites of genetic variation.
11
 The researcher would 
focus on a few candidate genes that were thought to affect the trait or disease of 
interest.
12
 The scope of inquiry was narrow and hence the likelihood of IFs was 
relatively low.
13
 However as a result of technological advances, making it possible to 
examine the human brain and the human genome in far greater detail than ever before, 
these research areas are expanding rapidly.
14
 With that expansion comes an increased 
likelihood that incidental findings will be detected.
15
 To illustrate, a 2010 meta-analysis 
of 16 studies involving 19,559 participants found that the prevalence of incidental 
findings on brain MRI was 2.7 per cent.
16
 With body MRI, the prevalence is 12.8 per 
                                                                                                                                           
(2011) 8 J Bioeth Inq 59 at 59. 
7
  Lisa S Parker “The Future of Incidental Findings: Should they be Viewed as Benefits?” (2008) 36 
J L M & E 341 at 342. 
8  Wolf and others, above n 5, at 219. 
9  Wolf, above n 1, at 217. 
10
  Karen Ross “When Volunteers Are Not Healthy” (2005) 6 EMBO Rep 1116 at 1116. 
11
  Wright Clayton, above n 2, at 287. 
12
  At 287. 
13
  At 287. 
14  Ross, above n 12, at 1116. 
15
  At 1116. 
16
  T C Booth and others “Incidental findings found in “healthy” volunteers during imaging 
performed for research: current legal and ethical implications” (2010) 83 Brit J Radiol 456 at 456. 
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cent and with CT colonoscopy, extra-colonic IFs require further investigation or medical 
intervention in 5 to 8 per cent of cases.
17
 Finally, family genetic studies reveal 
misattributed parentage at an estimated incidence of 10 per cent.
18
 
This paper focuses on IFs in two major research domains, genetic research and imaging 
research. Both empirical studies of IFs and normative discussion on how best to handle 
IFs are more advanced in imaging than in genetic research.
19
 This paper offers 
recommendations for how to anticipate and manage IFs in both research domains. What 
distinguishes the issue of IFs in genetic research from IFs in imaging and other research 
procedures is the likelihood and scope of potential IFs.
20
 In imaging research, the 
question is whether one of a limited number of IFs will occur.
21
 In the context of genetic 
research however, the question is how to deal with the hundreds of different IFs that can 
potentially be uncovered in any individual research participant’s genetic material.
22
 
Nevertheless, the analysis and recommendations presented in this paper are likely to 
have broader application to other domains of human subjects research.
23
  
The focus of this paper is on physiological and genetic IFs, rather than social or 
behavioural IFs. An example of the latter would be signs of alcohol abuse in an 
adolescent participating in an MRI study of adolescent cognition that is unrelated to 
alcohol use.
24
 Other examples include signs of physical abuse or suicidality in studies 
unrelated to those phenomena.
25
 Social and behavioural IFs raise somewhat different 
issues and are therefore not the focus of this paper. 
IFs can be clinically significant for a number of reasons. For example, an IF can indicate 
an urgent, clinically actionable condition such as a predisposition to non-polyp forming 
                                                
17
  At 456. 
18  Wolf, above n 1, at 216. 
19  Wolf and others, above n 5, at 220. 
20
  Elizabeth R Pike, Karen Rothenberg and Benjamin E Berkman “Finding Fault? Exploring Legal 
Duties to Return Incidental Findings in Genomic Research” (Legal Studies Research Paper, 
University of Maryland, 2013) at 4. 
21
  At 4. 
22  At 4. 
23
  Wolf and others, above n 5, at 220. 
24
  At 220. 
25
  Wolf and others, above n 5, at 220. 
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cancer, a cancer that is fatal and otherwise undetectable through standard screening.
26
 
An IF could predict a propensity to develop disease in the future, such as breast cancer 
or Alzheimer’s.
27
 Some IFs will reveal information that is not clinically significant, but 
may nevertheless have wide-reaching implications. An example of this is a finding of 
misattributed paternity. Yet other IFs, perhaps even most IFs, may instead be something 
the meaning and importance of which is unknown.
28
 When the consequence of the 
finding has clinical significance, research participants may benefit from learning about 
IFs discovered during the course of research. A research participant who learns that she 
has a BRCA mutation, an indication of a predisposition to developing breast cancer, for 
example, could take measures aimed at preventing undesirable future medical outcomes, 
including participation in regular mammogram screening.
29
 
IFs can occur in a variety of settings. They may indicate important clinically actionable 
results, or may instead be findings the meaning and importance of which are unknown. 
What is known, however, is that as technology develops, the frequency with which IFs 
are being uncovered is increasing. For this reason, it is important to develop a 
framework for their effective management.  
III The Current Situation 
The current framework relating to IFs is marked by a lack of clarity and an absence of 
consensus.
30
 Laws and regulations offer little guidance on how IFs should be managed.
31
 
The following section examines current international and domestic IF guidelines, and in 
doing so, illustrates the lack of coordination in this area.  
A Multilateral 
Since the late 19th century, biomedical research involving humans has been the subject 
of intense international ethical and legal debate.
32
 This has led to a number of regulatory 
                                                
26
  Pike, Rothenberg and Berkman, above n 20, at 3. 
27
  At 3. 
28
  At 3. 
29
  At 3. 
30  Susan M Wolf, Jordan Paradise and Charlisse Caga-anan “The Law of Incidental Findings in 
Human Subjects Research: Establishing Researcher’s Duties” (2008) 36 J L M & E 361 at 362. 
31
  At 362. 
32
  Heinrichs, above n 6, at 59. 
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frameworks, the most prominent being the Nuremberg Code, the Declaration of 
Helsinki, the Council of Europe’s Additional Protocol to the Convention on Human 
Rights and Biomedicine, concerning Biomedical Research and the Council for 
International Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines for Biomedical Research Involving Human Subjects.
33
 
The Nuremberg Code is a set of ethical principles for human experimentation created 
following the Nuremberg Trials at the end of World War Two. The Nuremberg Code 
emphasises the importance of voluntary consent. Article 1 provides that:
34
 
...before the acceptance of an affirmative decision by the experimental subject there 
should be made known to him… all inconveniences and hazards reasonable to be 
expected; and the effects upon his health or person which may possibly come from 
his participation in the experiment. The duty and responsibility for ascertaining the 
quality of the consent rests upon each individual who initiates, directs or engages in 
the experiment. 
Similarly, the Declaration of Helsinki (the Declaration) is a set of ethical principles 
developed for the medical community by the World Medical Association (WMA). 
Article 24 of the Declaration provides:
35
 
In medical research involving competent human subjects, each potential subject 
must be adequately informed of… any anticipated benefits and potential risks of 
the study and the discomfort it may entail, and any other relevant aspects of the 
study… After ensuring that the potential subject has understood the information, 
the physician or another appropriately qualified individual must then seek the 
potential subject’s freely given informed consent, preferably in writing. 
The Declaration has been described as “the most widely accepted guidance worldwide 
on medical research involving human subjects.”
36
 Though it is not a legally binding 
instrument at international law, along with the Nuremberg Code, the Declaration draws 
its authority from the degree to which it has been codified in, or influenced, national or 
                                                
33
  At 59. 
34  Nuremberg Code (1947), art 1. 
35
  Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects 
(adopted by the 18th WMA General Assembly, June 1964), art 24. 
36
  B Christie “Doctors revise Declaration of Helsinki” (2000) 321 BMJ 913 at 913. 
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regional legislation and regulations.
37
 In New Zealand, guidelines for health research 
released by the National Ethics Advisory Committee purport to accord with these key 
international instruments.
38
 
The Council of Europe’s Additional Protocol to the Convention on Human Rights and 
Biomedicine, concerning Biomedical Research (Additional Protocol to the Convention) 
provides:
39
 
If research gives rise to information of relevance to the current or future health or 
quality of life of research participants, this information must be offered to them. 
That shall be done within a framework of health care or counselling. In 
communication of such information, due care must be taken in order to protect 
confidentiality and to respect any wish of a participant not to receive such 
information. 
This provision emphasises the importance of notifying participants of “relevant” IFs. 
Nevertheless, it leaves unclear how investigators should determine what IF is “relevant” 
for each research participant.
40
 Moreover, the Additional Protocol to the Convention only 
applies to European Union states, and therefore excludes New Zealand. 
Finally, the CIOMS International Ethical Guidelines for Biomedical Research Involving 
Human Subjects recommends that individual participants be informed of “any finding 
that relates to their particular health status”.
41
 
Despite not expressly referring to IFs, these key international instruments nevertheless 
emphasise the necessity of, firstly, informing a participant of any anticipated benefits 
and risks of a study, and secondly, offering information relevant to a participant’s health 
                                                
37
  E Deutsch and J Taupitz “Freedom of control and biomedical research” (1999) 150 Bull Med 
Ethics 22 at 22. 
38  National Ethics Advisory Committee Ethical Guidelines for Intervention Studies: Revised edition 
(2012) at 1.7; National Ethics Advisory Committee Ethical Guidelines for Observational Studies: 
Observational research, audits and related activities (2012) at 1.6. 
39
  European Additional Protocol to the Convention on Human Rights and Biomedicine, concerning 
Biomedical Research 2005 ETS 195 (opened for signature January 25 2005, entered into force 
September 1 2007), art 27. 
40  Booth and others, above n 16, at 460. 
41
  Council for International Organizations of Medical Sciences in collaboration with the World 
Health Organization International ethical guidelines for biomedical research involving human 
subjects (2002) at 38. 
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or quality of life arising out of a study. The author submits that these provisions are 
sufficiently wide to include risk or presence of many IFs. Where an IF is a reasonably 
expected risk of a study, or if research gives rise to an IF of relevance to the current or 
future health or quality of life of a participant, according to the international framework, 
this information should be disclosed to the participant.  
The international framework detailed above has influenced legislative and regulatory 
systems worldwide. Many countries have enacted laws detailing the rights of research 
participants, and regulating at least some forms of human biomedical research.  
B New Zealand 
Human subjects research in New Zealand is comprehensively regulated. The current 
framework, however, is disjointed and lacks guidance on how IFs should be managed. 
1 Code of Health and Disability Services Consumers’ Rights 
The rights of health consumers and responsibilities of health care providers in relation to 
research are detailed in the Health and Disability Commissioner (Code of Health and 
Disability Services Consumers’ Rights) Regulations 1996 (the Code of Rights). The 
Code of Rights is established as a regulation under the Health and Disability 
Commissioner Act 1994, and sets out the rights of all health and disability services 
consumers, including those involved in teaching and research. 
The Code of Rights stipulates that every consumer has the right, and researchers a 
corresponding duty, to have services provided that comply with legal, professional, 
ethical and other relevant standards.
42
 Furthermore the Code of Rights provides that 
every consumer has the right to have services provided in a manner that minimises 
potential harm to, and optimises the quality of life of, that consumer.
43
 
                                                
42
  Health and Disability Commissioner (Code of Health and Disability Services Consumers’ Rights) 
Regulations 1996, sch, cl 2, right 4(2) (Code of Rights). 
43
  Schedule, cl 2, right 4(4). 
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The Code of Rights is based upon the central right of health care consumers to be fully 
informed in order to make an informed choice about the health and disability services 
they receive.
44
 The right to be fully informed is explicated in right 6, which provides:
45
 
(1) Every consumer has the right to information that a reasonable consumer, in 
that consumer’s circumstances would expect to receive, including –  
… 
(b)  An explanation of the options available, including an assessment 
of the expected risks, side effects, benefits and costs of each 
option; and 
… 
(d) Notification of any proposed participation in teaching or research, 
including whether the research requires and has received ethical 
approval; and 
… 
(f)  The results of tests; and 
(g)   The results of procedures. 
(2) Before making a choice or giving consent, every consumer has the right to 
the information that a reasonable consumer, in that consumer’s 
circumstances, needs to make an informed choice or give informed consent. 
Right 9 provides that the rights contained in the Code of Rights extend to those 
occasions when a consumer is participating in, or it is proposed that a consumer 
participate in research.
46
 Where the consumer is to participate in any research, informed 
consent must be in writing.
47
   
The focus of the Code of Rights is on the consumer and the information the consumer 
needs to be fully informed, not on whether the conduct of the provider is seen as 
                                                
44
  Katharine Greig “Informed Consent in the Code of Health and Disability Services Consumers’ 
Rights” (8 February 2000) <http://www.hdc.org.nz/education/presentations/informed-consent-in-
the-code-of-health-and-disability-services-consumers%27-rights>. 
45
  Code of Rights, sch, cl 2, right 6. 
46
  Schedule, cl 2, right 9. 
47
  Schedule, cl 2, right 7. 
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reasonable in the circumstances.
48
 There has been little case law in New Zealand dealing 
with this issue, however useful guidance can be gleaned from decisions in other 
jurisdictions.
49
 The patient-focused test developed in North American and Australian 
Courts, and in particular, draws on the decision of the High Court of Australia (HCA) in 
Rogers v Whitaker, which has since been applied in New Zealand.
50
 The HCA defined 
the level of detail required when informing individuals of the risks associated with a 
health service as:
51
 
Enough information… so that a reasonable person in the patient’s position, would, 
if warned of the risk, be likely to attach significance to it, or if the medical 
practitioner is or should be reasonably aware that the patient, if warned of the risk, 
would be likely to attach significance to it. 
In practice, the obligations under right 6 require the provider to make judgements as to 
the 'expected risks' associated with the procedure and what the 'reasonable consumer in 
the consumer's circumstances' would want to know. As with the international framework, 
the Code of Rights makes no explicit reference to IFs, however the author submits that in 
order to be fully informed, a reasonable consumer would want to know about the risk of 
IFs and how they would be managed, should results disclose their presence. 
Consequently, under right 6, IFs should be considered an ‘expected risk’. 
2 National Ethics Advisory Committee Guidelines 
Health and Disability Ethics Committees (HDECs) are responsible for ensuring that 
proposed health and disability research meets established ethical standards.
52
 These 
ethical standards are set out in guidelines authored by the National Ethics Advisory 
Committee (NEAC). Health and disability researchers, and not HDECs, however, are 
responsible for ensuring that their research meets these standards at all times. This 
responsibility is consistent with the aforementioned duty imposed on researchers by 
                                                
48
  Greig, above n 44.  
49
  Committee of Inquiry into Allegations Concerning the Treatment of Cervical Cancer at National 
Women’s Hospital and into Other Related Matters The Report of the Cervical Cancer Inquiry 
(Government Printing Office, July 1988) at 134. 
50  B v Medical Council HC Auckland HC 11-96, 8 July 1996 at 17. 
51
   Rogers v Whitaker (1992) 175 CLR 479 (HCA) at 490. 
52
  National Ethics Advisory Committee Ethical Guidelines for Observational Studies: 
Observational research, audits and related activities, above n 38, at Appendix 1. 
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right 4(2) of the Code of Rights.
53
 
The NEAC’s Ethical Guidelines for Intervention Studies and Ethical Guidelines for 
Observational Studies (the Guidelines), aim to contribute to better health outcomes in 
New Zealand by assisting researchers to perform sound studies.
54
 The Guidelines 
constitute ethical standards for the purpose of right 4(2) of the Code of Rights, meaning 
that consumers have a right, and researchers, a corresponding duty, to provide services 
in accordance with the Guidelines.
55
  
An intervention study is a study in which the researcher controls and studies an 
intervention provided to participants for the purpose of adding to knowledge of the 
health effects of that intervention.
56
 Many intervention studies are clinical trials.
57
 
Similarly, the primary purpose for observational research is to add to generalisable 
knowledge about a health or disability issue, and may include cohort studies
58
 and case 
control studies.
59
 Human subjects research may take the form of either an intervention or 
observational study.  
The Guidelines provide that information given to potential participants should outline 
the foreseeable risks and side effects of study participation, including any risks to the 
health of a participant’s family members.
60
 Importantly, if it is reasonably foreseeable 
that health problems previously unknown to the individual participant could be 
identified during the study process, the Guidelines state that arrangements for referral, 
                                                
53  Health and Disability Ethics Committee Standard Operating Procedures for Health and 
Disability Ethics Committees (2012) at [9]. 
54
  National Ethics Advisory Committee Ethical Guidelines for Intervention Studies: Revised 
edition, above n 38, at IV. 
55
  At 1.2. 
56  At 2.4. 
57  At 2.4. 
58
  Cohort studies examine the relationship between exposure to a factor or factors and the 
probability of the occurrence of a disease by observing large numbers of people over a period of 
time and comparing incidence rates of the disease in relation to exposure levels.  
59
  Case control studies examine the relationship between an attribute and a disease by comparing 
those with and without the disease with respect to the presence of the attribute or level of 
exposure to it.  
60
  National Ethics Advisory Committee Ethical Guidelines for Intervention Studies: Revised 
edition, above n 38, at 6.22. 
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with the individual’s consent, should be made.
61
 Furthermore, the Guidelines provide 
that participants (and their main care provider) must be informed of any clinically 
significant abnormal laboratory results or clinical observations that are detected during 
the course of a study.
62
 Finally, where participants are found, through the conduct of a 
study, to have a previously undetected health care need that is not directly related to the 
study, the Guidelines state that arrangements should be made for the participant to 
receive the necessary care.
63
 
The Guidelines provide researchers with explicit direction on how to address previously 
unknown health problems, and clinically significant abnormal results and observations. 
Many IFs will fit within one or both of these categories. Nevertheless, there are still 
issues left unresolved by the Guidelines. For example, it is not clear whether participants 
are supposed to be advised, during the informed consent process, of a researcher’s 
obligation to disclose any clinically significant abnormal results or observations. It is 
possible that a participant would not want to be informed of such a finding, and would 
therefore refuse to participate in research on that basis. The nature of the information 
conveyed during the informed consent process is, therefore, an area that requires further 
investigation. 
3 Operational Standards for Ethics Committees 
The essential elements of informed consent to participate in a health research 
investigation are further detailed in the Ministry of Health’s (MoH) Operational 
Standard for Ethics Committees (Operational Standard). This document provides 
guidelines for the constitution and operation of ethics committees reviewing health and 
disability research,
64
 and derives its public authority from the terms of reference of 
ethics committees established under s 11 of the New Zealand Public Health and 
                                                
61
  National Ethics Advisory Committee Ethical Guidelines for Intervention Studies: Revised 
edition, above n 38, at 6.71; National Ethics Advisory Committee Ethical Guidelines for 
Observational Studies: Observational research, audits and related activities, above n 38, at 9.1. 
62
  National Ethics Advisory Committee Ethical Guidelines for Intervention Studies: Revised 
edition, above n 38, at 6.68. 
63
  At 6.70. 
64
  Ministry of Health Operational Standard for Ethics Committees (Ministry of Health, Wellington, 
2006) at 1.2. 
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Disability Act 2000.
65
 The Operational Standard provides that in order for adequate 
information to be provided to a person for the purpose of gaining their informed consent, 
the information provided should include:
66
  
… 
iv. all foreseeable risks, side-effects or potential harm that are material to the 
research participant, and how significant risks will be monitored and 
managed; 
… 
xiii. the research participant’s access to research findings; 
xiv. the responsibilities of the researchers. 
The Operational Standard therefore does not explicitly require information about IFs to 
be provided to a prospective participant during the informed consent process. The 
Operational Standard does, however, provide that in general, researchers should be required 
to immediately report all serious or unanticipated adverse events to the ethics committee.67 
An adverse event includes an undesirable and unintended result of therapy or other 
intervention,
68
 and could therefore include the discovery of an IF. The Operational 
Standard does not, however, include an obligation to disclose the event to the research 
participant themselves. 
4 Health Information Privacy Code 1994 
Research involving the use of personal health information must comply with the Health 
Information Privacy Code 1994 (HIPC).
69
 ‘Health information’ includes information 
concerning:
70
 
(a) information about the health of that individual, including his or her medical 
history; or  
… 
                                                
65
   At 1.0. 
66
  At 2.2. 
67  At 6.6. 
68
  At 98. 
69
  Health Research Council of New Zealand Guidelines on Ethics in Health Research (2005) at 4.1. 
70
  Health Information Privacy Code 1994, cl 4(1). 
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(d) information provided by that individual in connection with the donation, by 
that individual, of any body part or any bodily substance of that individual or 
derived from the testing or examination of any body part, or any bodily 
substance of that individual; or 
(e) information about that individual which is collected before or in the course of, 
and incidental to, the provision of any health service or disability service to 
that individual. 
For the HIPC to apply to health research, the researcher must be a ‘health agency’, and 
the information must be ‘health information’. If the research falls outside either of these 
definitions, the HIPC will not apply.
71
 Health information, has at the core of its 
definition, the notion that the information relates to an identifiable individual.
72
 IFs 
concern the health of an individual, as required by cl 4(1)(a), and therefore fit within the 
definition of ‘health information’. Moreover, a researcher will be a ‘health agency’ if 
they provide health or disability services.
73
 Health and disability services include 
services provided to an individual for the purpose of improving or protecting the health 
of that individual or the public.
74
 The purpose of human subjects research is to create 
generalisable knowledge which advances the public good.
75
 Consequently, human 
subjects researchers are likely to fit within the definition of a ‘health agency’. 
Under the HIPC, an individual has rights of access to their own health information.
76
 In 
all situations other than where an individual seeks access to their own health 
information, r 11 applies. Rule 11 places limits on the disclosure of health information, 
and applies in situations where a health agency proposes to volunteer information to the 
individual or to a third party, or a third party has requested access to a person’s health 
information. The underlying premise of this rule is that health agencies must not disclose 
individuals’ health information unless they have good reason in terms of the exceptions 
                                                
71
  Health Research Council of New Zealand, above n 69, at 5.10. 
72
  At 5.10. 
73  Health Information Privacy Code, cl 4(2)(a). 
74
  Clause 3. 
75
  Pike, Rothenberg and Berkman, above n 20, at 41. 
76
  Health Information Privacy Code, r 6. 
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that the rule provides.
77
 For the purposes of this paper, the following exceptions may be 
relevant:
78
 
(1) A health agency that holds health information must not disclose the information 
unless the agency believes, on reasonable grounds, that – 
(a) The researcher might disclose the information to the individual; or 
(b) The individual concerned, or the individual’s representative, may 
authorise disclosure; or 
… 
(2) Compliance with subrule (1)(b) is not necessary if the health agency believes on 
reasonable grounds that it is either not desirable or not practicable to obtain 
authorisation from the individual concerned and that –  
        … 
(c) the disclosure of information is necessary to prevent or lessen a 
serious or imminent threat to –  
(i) public health or public safety; or 
(ii) the life or health of the individual concerned or another 
individual. 
5 University of Auckland Guiding Principles 
The majority of health research on human subjects requires ethics committee approval 
in order to proceed. The University of Auckland Human Participation Ethics 
Committee (UAHPEC) is one ethics committee that guides prospective researchers as 
to how they should address IFs. In its Guiding Principles for Conducting Research with 
Human Participants UAHPEC provides:
79
 
UAHPEC uses the standard of more-than-minimal risk to identify incidental 
findings: if a contingency is more likely to arise due to participation in the study 
than it would in everyday life outside of the study, then it deserves special 
attention. 
                                                
77  Health Research Council of New Zealand, above n 69, at 5.17. 
78
  Health Information Privacy Code, r 11. 
79
  University of Auckland: Human Participants Ethics Committee Guiding Principles for 
Conducting Research with Human Participants (March 2013) at 5.13. 
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Further, UAHPEC expects researchers to have clear policies and procedures in place to 
allow them to identify and address IFs.
80
 The researcher must indicate to UAHPEC how 
likely an IF may be, and how large the impact of the finding may be on the 
participant.
81
 If researchers believe there is a reasonable probability of IFs, they have a 
responsibility to inform the participant of this in advance.
82
 If a participant does not 
wish to be informed of such a finding, UAPHEC advises researchers that the participant 
should be excluded from the research.
83
  
According to the UAHPEC policy, in the event of an IF, researchers are expected to 
advise the participant within the limit of their expertise and put the participant in 
contact with appropriate assistance.
84
 It appears that researchers are equally expected to 
apply this approach in the event of an unexpected IF. Consequently, a participant who 
had not been informed of the risk of a particular IF, as it was not considered reasonably 
probable, will nevertheless be advised of its presence. This approach raises a number of 
ethical issues, which will be discussed in Part IV. 
6 General Comments 
Whilst New Zealand comprehensively regulates human subjects research, there is an 
absence of guidance on how to manage IFs. Direction on the information researchers 
should provide to participants is inconsistent, and there is no clear process to be 
followed upon identification of an IF. Under the current framework, it is up to individual 
ethics committees, such as the UAHPEC, to individually implement policies relating to 
the management and disclosure of IFs. Furthermore, there is no indication whether a 
research participant may refuse to be told about IFs. Consequently, research participants 
are not necessarily receiving enough information to be fully informed, and provide 
informed consent for the purposes of the Code of Rights. More generally, under the 
current system, the rights and interests of research participants are not receiving 
sufficient protection. 
                                                
80
  At 5.13. 
81  At 5.13. 
82
  At 5.13. 
83
  At 5.13. 
84
  At 5.13. 
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C Overseas Jurisdictions 
It is valuable to briefly examine how other states have regulated human subjects research 
and, in particular, IFs. The United States and the United Kingdom are both at the 
forefront of medical research, yet as will be shown, their frameworks for managing IFs 
are similarly ambiguous. 
1 United States 
Much of the legal discussion involving IFs in the United States (US) has been framed in 
terms of federal Common Rule requirements contained in the Code of Federal 
Regulations.
85
 Before a researcher conducts any research on a human subject, the 
Common Rule requires a researcher, during the consent process, to provide subjects with 
a description of any reasonably foreseeable risks or discomforts and a description of any 
benefits that may reasonably be expected from the research.
86
 The Common Rule does 
not, however, directly address the process to be followed when a researcher identifies an 
IF, nor the scope of disclosure to a research participant. Further, the Common Rule does 
not specify whether research participants may refuse to be told about IFs. 
In the US, ethics committees are known as Institutional Review Boards (IRBs). In one 
study regarding IRB conduct and IFs, twenty-nine IRB Chairs were asked what 
information, if any, their IRBs required researchers to include in informed consent 
documents with respect to IFs.
87
 Only one Chair reported that their IRB had IF-specific 
requirements, yet described this requirement as relatively informal:
88
 
To my knowledge it’s not a formal requirement, but it is something that we do so 
routinely that it’s become a de facto requirement… We always require a full 
statement of risk and this would include in genomic incidental findings the risk of 
job discrimination, the risk of, you know, future anxiety, concern and stress, 
emotional reaction to the news, risk of insurance loss. 
                                                
85
  Stacey A Tovino “Incidental Findings: A Common Law Approach” (2008) 15 Acc Res Pol Qua 
Ass 242 at 259.  
86  45 CFR 46 (2008), § 46.116 (a). 
87
  Christian M Simon and others “Informed Consent and Genomic Incidental Findings: IRB Chair 
Perspectives” (2011) 6 J Empir Res Hum Res Ethics 53 at 60 
88
  At 60. 
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The remaining Chairs reported that their IRBs had no requirements relating to IFs or that 
their IRB requirements were “limited, indirect, and relatively generic.”
89
 
Similarly to New Zealand, US regulations do no explicitly require researchers to discuss 
with participants the risk of IFs or the researcher’s policy for disclosure of IFs. Individual 
IRBs are left to implement their own policies, with very few, it seems, addressing IFs 
specifically.  
2 United Kingdom 
Guidance on the management of IFs in the United Kingdom (UK) is inconsistent and 
difficult to find.
90
 Both the UK Department of Health and the National Research Ethics 
Service (NRES), however, require that research participants be made aware of possible 
disadvantages and risks of taking part in research.
91
 These risks include the discovery of 
another condition of which the participant is unaware, which might have medical or 
insurance implications.
92
 Participants must also be informed about the arrangements for 
dealing with such a discovery.
93
 Despite this, there is evidence of variations in 
understanding on the issue of IFs, and consequently in the management of findings.
94
 
The NRES suggests that researchers explain to participants if their general practitioner 
(GP), or other health care practitioner, needs to be notified of their involvement and to 
seek consent for this notification.
95
 They further advise that researchers should explain 
to participants what information will be exchanged.
96
 Nevertheless, it is unclear from 
this statement whether the GP is informed merely that the participant has taken part in 
research, or whether the GP is informed of all results, including IFs.  
The Medicines and Healthcare Products Regulatory Authority recommends that 
researchers have policies in place that facilitate the disclosure of IFs when identified in 
                                                
89  At 60. 
90  Royal College of Radiologists “Management of Incidental Findings Detected During Research 
Imaging” <http://www.rcr.ac.uk/publications.aspx?PageID=310&PublicationID=357> at 30. 
91
  At 9. 
92
  At 9. 
93
  At 9. 
94  At 9. 
95
  National Research Ethics Service – National Patient Safety Agency Information Sheets and 
Consent Forms: Guidance for Researchers and Reviewers (March 2011) at 6.2.5. 
96
  At 6.2.5. 
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participants undergoing MRI.
97
 Furthermore the Authority provides this should be 
followed by appropriate onward referral.
98
 There are no other explicit UK 
recommendations to disclose IFs to research participants unless the participant 
specifically requests disclosure.
99
 In such a case, the participant would have a right, 
under the Data Protection Act 1998, to have access to IFs.
100
 
Therefore, in the UK, although researchers are required to warn prospective research 
participants of the risk of IFs, unless a participant explicitly requests disclosure, there is 
no law requiring IFs to be disclosed to them. 
D Conclusion 
Current law and regulations, both in New Zealand and internationally, offer little direct 
guidance on how to address IFs in the research setting. In the majority of cases, any 
requirement to advise participants of the risk of IFs must be implied from a general 
obligation to advise of the risks of a research procedure. The nature and extent of 
information participants receive currently appears, in most cases, to be determined by 
the conducting research team and presiding ethics committee. This is unsatisfactory as, 
like has been illustrated in the US, participants will receive more or less information 
depending on the research team or ethics committee. If, when deciding whether to take 
part in a research procedure, participants do not receive all relevant information, they are 
not fully informed. Under New Zealand law, proceeding with research on this basis 
would amount to a breach of the Code of Rights. In order to improve this situation, a 
comprehensive regulatory framework guiding the management of IFs is required. 
IV Towards a Comprehensive Approach – Important Considerations 
As has been discussed above, the current lack of consensus and absence of uniform 
standards for IF management is problematic. The absence of a concrete regulatory 
framework can mean that researchers encountering IFs are uncertain about what to do 
with the information. Not only is current guidance unclear, but in many circumstances 
                                                
97
  Medicines and Healthcare Products Regulatory Authority Safety Guidelines for Magnetic 
Resonance Imaging Equipment in Clinical Use (December 2007) at 4.10.1. 
98
  At 4.10.1. 
99
  Booth and others, above n 16, at 460. 
100
  Data Protection Act 1998 (UK), s 7. 
Incidental Findings in Human Subjects Research: Is Ignorance Really Bliss? 
 
 23
the participant’s wishes would not have be ascertained. In determining the most 
appropriate approach for the management of IFs however, a number of important issues 
require consideration. The next section of this paper will address these issues. 
A What to Disclose? 
Under the Code of Rights, a prospective research participant in New Zealand has a right 
to the information that a reasonable consumer, in that consumer’s circumstances, would 
expect to receive.
101
 If a research participant does not receive this information, they are 
not adequately informed for the purposes of giving informed consent, and should not, 
therefore, partake in the research.
102
 The author has already proposed, that a reasonable 
consumer would expect to be advised about the possibility of IFs. Researchers should be 
required to discuss the potential for IFs with participants during the informed consent 
process. Researchers should also identify and discuss with participants any IFs that may 
reasonably be expected to flow from the research procedure. If an IF is not reasonably 
foreseeable, it need not be raised. Finally, during the informed consent process, the 
researcher should discuss with the participant the extent to which IFs will be disclosed. 
The following section focuses on this issue, and examines the various approaches to 
disclosure that could be adopted. 
1 Return no IFs 
There are a number of possible approaches to the determination of which IFs, if any, 
should be disclosed to a research participant. The first possibility is that researchers not 
return any IFs to participants, regardless of the seriousness of the finding. A strength of 
this approach is that it acknowledges the difficulties inherent in tracking down and 
locating large numbers of participants, and the large amounts of resources, both time and 
money, needed to analyse and return the thousands of variants that could arise in any 
given research participant’s sample.
103
 A further advantage is that this approach 
allocates resources appropriately. Returning IFs diverts funds away from research, the 
purpose of which is to create generalisable knowledge that advances the public good.
104
 
                                                
101  Code of Rights, sch, cl 2, right 6(2). 
102
  Schedule, cl 2, right 7(1). 
103
  Wolf, Paradise and Caga-anan, above n 30, at 364. 
104
  Pike, Rothenberg and Berkman, above n 20, at 41. 
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These funds are redirected to the process of returning IFs, which generally only benefits 
particular individuals.
105
 Finally, this approach recognises the distinction between 
research and clinical care, and does not contribute to the therapeutic misconception.
106
 
The idea of a therapeutic misconception involves the mistaken conflation of medical 
research with clinical care,
107
 and will be discussed in greater detail later in this part.
108
  
This approach also has a number of disadvantages. First, given emerging ethical 
guidance that encourages the return of results in certain circumstances, and the fact that 
some researchers have already started returning IFs, it may be unrealistic to conclude 
that researchers should not return IFs, particularly where the IF is serious or life-
threatening.
109
 The reason that some researchers started returning IFs was because they 
felt morally bound to return those with significant health implications.
110
 Creating a 
standard whereby researchers are not expected to return IFs may consequently lead 
researchers to compromise their moral conviction. Moreover, this approach does not 
address a participants’ reasonable expectations that someone with particularised 
knowledge and skills, who is granted access to otherwise private health information, 
would inform them of any significant health problems.
111
 For these reasons, not 
returning IFs irrespective of their severity is arguably unethical.
112
 
2 Return all research data without interpretation 
An alternative approach is an obligation to return all data without interpretation. This 
approach responds to arguments by some that participants prefer to receive significantly 
more information than has generally been returned, even if the information is not 
clinically actionable.
113
 Such an approach, though rarely considered, does have some 
advantages. First, it allows researchers to fulfil their moral convictions by returning 
information to participants while minimising the burden of doing so. At least in the case 
                                                
105  At 41. 
106  At 41. 
107
  At 12. 
108
  See Part V (C)(1). 
109
  Pike, Rothenberg and Berkman, above n 20, at 41. 
110
  At 41. 
111  At 41. 
112
  Laura M Beskow and Wylie Burke “Offering Individual Genetic Research Results: Context 
Matters” (2010) 2 Sci Transl Med 1 at 1-2. 
113
  At 1. 
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of genetic data, websites and services are increasingly allowing individuals to obtain 
reasonably priced interpretations, meaning that participants can control when and 
whether they learn more about their genetic information.
114
 This approach also removes 
any potential obligation to re-examine and re-notify participants with updated analyses 
as additional knowledge is acquired.
115
 Participants have access to their own data and 
can seek out their own re-examination in line with evolving science.
116
 
This approach also has drawbacks. First, returning all data without interpretation may 
not satisfy a researcher’s moral conviction, as they will not be responsible for alerting 
research participants to IFs that have significant health implications.
117
 Furthermore, 
handing information to participants without any interpretation may overwhelm those 
who do not know where to turn for interpretation, or who may get it interpreted without 
appropriate guidance about what the information means.
118
 Finally, returning all data to 
individual research participants may be technologically and logistically difficult and 
expensive, particularly where studies involve thousands of participants.
119
 
Both full disclosure and complete nondisclosure of IFs are therefore problematic 
approaches. Failure to disclose medically relevant IFs cannot be ethically justified, and 
full disclosure, in addition to being costly and time-consuming, fails to ensure 
participants receive appropriate counselling and support in the interpretation of research 
data. 
3 Disclosure determined by clinical benefit 
A majority view is emerging among scholars, practitioners, and advisory bodies that 
researchers have an ethical obligation to offer to return some IFs.
120
 It has been 
submitted that IFs can be divided into three categories: those that offer strong net benefit 
and should be disclosed, those that offer possible net benefit and may be disclosed, and 
finally, those that are unlikely to offer net benefit and therefore should not be 
                                                
114
  Pike, Rothenberg and Berkman, above n 20, at 42. 
115
  At 42. 
116
  At 42. 
117
  At 43. 
118  Interview with Ingrid Winship, Inaugural Chair of Adult Clinical Genetics University of 
Melbourne (Kathryn Ryan, Nine to Noon, National Radio, 13 August 2013).  
119
  Pike, Rothenberg and Berkman, above n 20, at 43. 
120
  At 16. 
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disclosed.
121
 The argument put forward by health professionals is that categorising 
disease types into these packages is an appropriate way to determine which IFs should 
be disclosed to participants.
122
  
Nevertheless, these terms still leave a lot open for interpretation.
123
 For example, what 
constitutes a strong net benefit? Must the consequences be life and death? Or is a 
reduced chance of contracting a disease that causes discomfort sufficiently significant? 
Furthermore, must the IF have individual significance, or is reproductive significance 
sufficient?
124
 
An IF whose disclosure offers strong net benefit can be defined as one revealing a 
condition likely to be serious or life-threatening that can be avoided or ameliorated.
125
 
This category would also include genetic information that could be used in reproductive 
decision-making to avoid grave risk to offspring.
126
 Under this approach, the researcher 
should advise the participant of an intention to disclose an IF in this category during the 
informed consent process. In genetic studies, an IF of genes associated with hereditary 
cancer would be in this category, as it reveals a condition likely to be life threatening or 
to impose grave harm that may be avoided by alerting the research participant.
127
 
An IF that offers possible net benefit is one that may offer more benefit than burden to a 
research participant.
128
 Researchers should discuss the possibility of revealing such IFs 
with participants during the informed consent process, where an approach should be 
agreed upon.
129
 This category includes genetic information revealing a significant risk of 
a condition likely to be grave or serious that cannot be avoided or ameliorated, but 
which a research participant is likely to consider important.
130
 An IF that indicates a 
participant’s susceptibility to Alzheimer’s disease at some point in the future would 
                                                
121
  Wolf and others, above n 5, at 238.  
122
  Anne Townsend and others ““I Want to Know What’s in Pandora’s Box”: Comparing 
Stakeholder Perspectives on Incidental Findings in Clinical Whole Genomic Sequencing” (2012) 
158 Am J Med Genet A 2519 at 2523. 
123
  Pike, Rothenberg and Berkman, above n 20, at 15. 
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come within this category.
131
 This category also includes genetic information of a 
condition likely to be serious that can be used in reproductive decision-making to avoid 
significant risk for offspring.
132
 
Finally, IFs that are unlikely to have net benefit should not be disclosed to research 
participants.
133
 The rationale behind withholding disclosure is an absence of a 
justification for subjecting the research participant to the anxiety and burden of receiving 
this information.
134
 A participant should be advised of a policy against disclosure during 
the informed consent process.
135
 In this category are IFs that are not likely to be of 
serious health or reproductive importance.
136
 An IF of misattributed paternity would 
usually fall within this category.
137
  
The balance between the risk and benefit of disclosing IFs, therefore, depends on the 
significance of findings in the diagnosis of disease and the impact of early intervention 
on outcome.
138
 Early identification of an IF might be of unequivocal benefit to the 
participant if the condition is treatable and early diagnosis improves the outcome. For 
example, renal cell carcinoma, a common type of kidney cancer, can be detected earlier 
with imaging than at symptomatic presentation, with a consequent significant 
improvement in prognosis.
139
 Many incidental neuroimaging findings are, however, of 
indeterminate clinical significance,
140
 with poorly characterised natural history and 
unpredictable individual outcomes; thus, treatment is of questionable benefit.
141
 
Despite the view of many health professionals that categorising disease types is an 
appropriate way to determine which IFs should be disclosed, public attitudes indicate 
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  At 239. 
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  Booth and others, above n 16, at 459. 
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  At 460. 
140  Jason M Royal and Bradley S Peterson “The Risks and Benefits of Searching for Incidental 
Findings in MRI Research Scans” (2008) 36 J L M & E 305 at 309. 
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  A Kleinschmidt “Incidental Neuroimaging Findings: Lessons from Brain Research in 
Volunteers” (2007) 20 Curr Opin Neurol 387 at 388. 
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that disclosure should not be based on clinical indicators alone.
142
 Members of the public 
have emphasised the subjectivity of such categorisations.
143
 It is argued that as 
individuals interpret “relevance” and “seriousness” differently, participants should not 
be presented with pre-categorised packages that have been filtered by professionals.
144
 
Research has shown that the public’s preference is for disclosure of IFs in general.
145
 A 
recent study surveying public attitudes to IFs from hypothetical testing found that 69 per 
cent of the public wanted information about IFs where the risk of the IF was unclear. 
Nevertheless, 96 per cent of respondents wanted information about serious and treatable 
diseases,
146
 thus lending support to the profession’s proposal to categorise findings. 
For the public, the importance of personal choice was associated with ownership. One 
study participant questioned why it was even an issue of the doctor having a say, as it is 
the individual’s body.
147
 Participants indicated the importance of control and that 
nobody was entitled to make decisions for them:
148
 
 … we get back to the whole issue of choice. Whose position is it to dictate 
what kind of knowledge we have about ourselves, whether it’s medical or 
otherwise? ... Not to have that choice to know about yourself. That… is an 
element of control that I don’t want anybody having other than me. 
The difficulty with this approach, however, is determining at what point a participant 
makes their disclosure decisions. Realistically, this must take place during the informed 
consent process. If it were left until after the research had been conducted, researchers 
would presumably not seek a participant’s preference unless they had in their possession 
knowledge of IFs that they believed warranted disclosure. Consequently, participants 
may become concerned as to why a researcher is seeking their preference, and may feel 
obliged to elect for disclosure.  
                                                
142  Townsend and others, above n 122, at 2521. 
143
  At 2523. 
144
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  At 2523. 
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  S B Haga and others “Public Attitudes toward Ancillary Information Revealed by 
Pharmacogenetic Testing under Limited Information Conditions” (2011) 13 Genet Med 723 at 
723. 
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Although health professionals support participant choice, it has been emphasised that 
what participants want to know should be balanced against what information they are 
entitled to have.
149
 On this point, it is argued that participants should have a 
“reasonable” amount of freedom in deciding what information will be disclosed to 
them.
150
 This argument is based on logistics, and the fact that resources are not yet 
sufficient to analyse all data that is received, and return it in an understandable way.
151
 
Health professionals also feel that full disclosure will mean sharing data of unknown 
significance that could be burdensome or meaningless for participants.
152
 
What can be taken from this is that there is a feeling within the public that participant 
choice, underpinned by autonomous decision-making, and not clinical benefit should be 
the criterion for disclosure of IFs.
153
 Conversely there is agreement within the body of 
health professionals that clinical benefit should be the determining factor in the extent to 
which IFs are disclosed to research participants. 
4 An obligation to search for IFs? 
Assuming there is some obligation to disclose certain IFs that are discovered in the 
course of research, the next question is whether there ever is or should be a positive 
obligation to search for these findings?  In other words, when researchers generate and 
analyse data, do they have an obligation to actively look within the data for potential 
indications of disease?
154
 Whilst the standard view has been that researchers generally 
have no obligation to act as health professionals and actively search for IFs, but this 
assumption appears to be changing.
155
 This gives rise to a fourth potential approach to IF 
disclosure, involving researchers returning a pre-determined selection of IFs listed in a 
compendium. 
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This approach is gaining popularity in genetic research, with a number of groups having 
discussed the possibility of building standard lists of genetic variants that could or should 
be disclosed as IFs. The American College for Medical Genetics (ACMG), for example, 
recommends that for any evaluation of clinical sequencing results, a minimum list of 57 
conditions, genes and variants should be examined and the results disclosed.
156
 The 
conditions are those that the ACMG considers most likely to be verifiable by other 
diagnostic methods and amenable to medical intervention.
157
 It is estimated, from a 
limited amount of published data, that approximately one per cent of genetic sequencing 
reports will include an IF from this list.
158
  
In support of guidelines such as those proposed by the ACMG, it has been said that they 
“represent an initial attempt to set a professional standard for best laboratory practices 
that will responsibly minimise variation in laboratory analysis and reporting of clinically 
beneficial IFs.”
159
 While this approach establishes an obligation on the part of the 
researchers to search for findings, it is argued that the obligation is narrow and confined 
to those specific variants that are well characterised and understood.
160
 This approach is 
also likely to satisfy a researcher’s moral convictions about returning IFs with important 
health implications.  
While most agree that there need to be standards, critics say that the recommendations 
run afoul of personal autonomy,
161
 and that returning IFs without participant consent is 
misguided.
162
 This is because the recommendations do not consider participant 
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preferences in reporting results. Under the ACMG approach, participants will receive all 
recommended results whether or not they have expressed a preference.
163
  
This approach would also be labour intensive. Each list’s content would need to be 
regularly re-examined and modified, in order to remain consistent with evolving 
science.
164
 As compendia would evolve over time, it is unclear whether researchers 
would have an ongoing obligation to re-examine participant data in light of changes to 
the compendium.
165
 Furthermore, there would likely be an increase in the costs 
associated with research procedures.
166
 As these costs would not necessarily relate to the 
object of the study, it is unclear where this additional funding would come from. Those 
who fund research projects may be reluctant to contribute more money so that individual 
participants can be tested for specific health conditions.  
Finally, it is argued that this approach gives a new meaning to the term ‘incidental 
finding’.
167
 Rather than reporting findings that are incidental to the purpose of the 
research, laboratories will be undertaking a deliberate search for pathogenic or likely 
pathogenic indicia. Even this level of return may contribute to the therapeutic 
misconception, with research participants relying on researchers and the research process 
in a way that was not intended.
168
  
Similarly in the imaging context, it has been argued that radiologists should be engaged 
to read all scans.
169
 This would provide the surest means of protecting participants from 
unidentified but potentially life-threatening conditions that may appear as IFs.
170
 
Resistance to routine readings by radiologists has been fuelled in part by the cost, both 
financial and logistical, of engaging radiologists to analyse all scans.
171
 An associated 
reality is that the costs of such a policy may, in the future, determine which researchers 
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can conduct research, and whether projects actually receive required levels of funding.
172
 
Nevertheless, such readings would maximise benefits and minimise risk to participants, 
as they would provide the best chance for IF identification.
173
 Many imaging researchers 
accept the validity of this argument, but also acknowledge the logistical and financial 
difficulties that accompany it.
174
 
5 A Right not to Know? 
Discussion up until this point has proceeded largely on the assumption that the 
researcher or research team is responsible for determining the extent to which IFs are 
disclosed to research participants. But what gives them this right? To the contrary, 
respect for the autonomy of the research participant suggests that the participant, not the 
research team, should have the discretion to decide whether or not an IF is disclosed.
175
 
If a participant has explicitly indicated that he or she does not wish to receive 
information regarding IFs, should individual autonomy take precedence over a 
researcher’s desire to discharge their perceived ethical obligation by disclosing a 
clinically relevant IF?  
These questions raise the issue of a right not to know information about oneself, and 
offer a further reason why caution should be exercised in the disclosure of IFs in the 
research setting. The right not to know is a well-established element of modern medical 
ethics and medical law.
176
 The Council of Europe’s Convention on Human Rights and 
Biomedicine, for example, provides that “everyone is entitled to know any information 
collected about his or her health. However, the wishes of individuals not to be so 
informed shall be observed.”
177
 The right not to know applies not only to patients but 
also to research participants. The Additional Protocol to the Convention provides:
178
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If research gives rise to information of relevance to the current or future health or 
quality of life of research participants, this information must be offered to them… 
In communication of such information, due care must be taken in order to protect 
confidentiality and to respect any wish of a participant not to receive such 
information. 
The CIOMS and other international guidelines also recognise that the wishes of 
individuals not to be informed should be respected.
179
  
The impact of IF disclosure depends on the circumstances and values of the person 
concerned. As a result, it is argued that it is ethically right that it is the individual 
participant who decides whether or not they wish to know the results of medical 
research.
180
 Even if treatment exists and, from a medical point of view, it may thus seem 
irrational to limit one’s options by not knowing about a health condition, it is 
nevertheless argued that the decision whether or not to obtain information rests with the 
individual alone,
181
 and only in exceptional circumstances may restrictions be placed by 
law on the interests of the participant.
182
 
In some contexts, however, the right not to know can become highly problematic. 
Consequently, it is doubtful whether a strict adherence to the right not to know is 
feasible.
183
 For example, the situation can become particularly troubling if a researcher 
has reason to believe that an IF threatens the research participant’s life and has the 
potential to be dangerous for other persons. In such circumstances, the conflict between 
the principles of personal autonomy and non-malfeasance becomes evident.
184
 The 
question then becomes whether it is possible to avoid the described conflict of principles 
or, if this is not the case, how the conflict should be resolved.
185
 
The WMA, which represents approximately 80 national medical associations, including 
New Zealand, does not respect refusal by an individual to receive IFs if disclosure is 
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“required for the protection of another person’s life.”
186
 An example of such a situation 
would be a potentially epileptogenic brain tumour in a bus driver who happened to be a 
research participant.
187
 Even if this person did not wish for findings to be disclosed to 
them, according to the WMA, there would be an ethical duty to do so, with lives of 
others being put at risk if the IF is left undisclosed.
188
 
Some writers have argued that an insistence on the right not to know by potential 
research participants should be an exclusion criterion.
189
 This would mean that people 
who do not wish to be informed of IFs would be unable to take part in the research. This 
solution incorrectly assumes, however, that a person is held to what they agree to during 
the informed consent process.
190
 Just as a participant is able to withdraw consent to a 
procedure,
191
 the health consumer focus in the Code of Rights suggests that participants 
would also be able to alter their preferences relating to IF disclosure. Taking the right 
not to know as an exclusion criterion may raise a further problem. Generally, only 
scientific parameters relevant to the experiment can serve as exclusion criteria in 
research projects.
192
 To draw on other facts could be seen as a form of discrimination.
193
 
It therefore seems preferable to look for a different approach. 
The aforementioned ACMG recommendations are an example of where participant 
preference is not taken into account when determining whether IFs are disclosed. Whilst 
recognising that this approach may violate existing ethical norms regarding personal 
autonomy, the ACMG felt that in selecting a minimal list weighted toward conditions 
where prevalence was high and intervention may be possible, there existed a fiduciary 
duty to prevent harm by warning participants, and that this principle superseded 
concerns about autonomy.
194
 The ACMG recommendations consequently provide that 
laboratories seek and report findings from the pre-determined list without reference to 
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participant preferences.
195
 Participants have the right to refuse consent to the procedure 
if they judge the risks of possible discovery of IFs to outweigh the benefits of testing.
196
 
Once one acknowledges that it will sometimes be impossible to avoid a conflict between 
the principles of self-determination and non-malfeasance an alternative approach 
becomes clear. This approach requires the possibility of conflicts of principles to be 
made explicit during the informed consent process.
197
 Potential research participants 
should be informed that they have a right not to know and that researchers will respect 
this right unless concealing an IF could be immediately life threatening or comparably 
dangerous for them or third persons.
198
 Research participants should be made aware that 
in such cases the principle of non-malfeasance would outweigh their right to 
informational self-determination. On this basis, the participant should decide whether or 
not they want to participate in the research project. This approach has the benefit of 
establishing the circumstances in which the right not to know will be suspended. By 
doing so, it avoids the need to re-consult participants to ask them whether they adhere to 
their initial decision, and in doing so implying there is something that should be 
revealed.
199
  
This approach accords with that contained in the HIPC. As already discussed, r 11 of the 
HIPC places limits on the disclosure of health information.
200
 The underlying premise of 
this rule is that health agencies must not disclose individuals’ health information unless 
they have good reason in terms of the exceptions that the rule provides.
201
 The rule 
provides an exception where the researcher discloses the information to the individual 
concerned.
202
 Therefore in circumstances where concealing an IF could be immediately 
life threatening or comparably dangerous for the individual or a third party, disclosure of 
the IF to the individual despite an individual “opting-out” of disclosure will not amount 
to a breach of the HIPC. 
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Including an “opt-out” provision in the informed consent document, whereby 
participants can choose not to have IFs disclosed to them, and accompanying this with a 
discussion on when, nevertheless disclosure of IFs will be made, may therefore strike an 
appropriate balance between personal autonomy and non-malfeasance. Although a 
default obligation to disclose clinically beneficial IFs is arguably most desirable from a 
researcher’s perspective, it is, nevertheless, important to give deference to individual 
autonomy. 
6 Misattributed Paternity 
The most common IF in genetics research is misattributed paternity.
203
 For years, partial 
or complete non-disclosure of such findings has been the most common practice in both 
the clinical and research settings.
204
 For example, if a husband is found not to carry a 
genetic mutation that affects a child born to his wife, he is frequently told only that the 
recurrence risk is very low.
205
 The wife, however, may be told individually about the 
finding of misattributed paternity, which she can then address as she sees fit.
206
 Non-
disclosure is even more common in the research setting.
207
 The foundations of this 
practice lie in a researcher’s concern that revealing misattributed paternity will disrupt 
the family, as well as a desire to avoid getting involved in difficult situations.
208
 This 
approach has been criticised for undermining the man’s and child’s right to know about 
their biological connections.
209
  
As misattributed paternity is the most common IF in genetics research, it is reasonable to 
expect researchers to warn prospective participants about the risk of uncovering such a 
finding. Ethics committees increasingly do, in fact, require the possibility of discovering 
misattributed paternity to be included in research consent forms.
210
 With knowledge of 
this possibility, individuals are better equipped to make an informed decision as to 
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whether or not to participate in the research.
211
 If genetic testing does reveal an IF of 
misattributed paternity, the author proposes that the same standard should be applied to 
this IF as any other. If disclosure is to be determined by clinical benefit, for example, 
this approach should also be applied to an IF of misattributed paternity. 
B Parties involved in disclosure 
Once it has been determined that an IF warrants disclosure, the regulatory framework 
should also detail who is responsible for disclosure, and to whom disclosure should be 
made. 
1 Who should disclose IFs? 
There appears to be consensus, internationally, that a researcher is not the appropriate 
person to disclose IFs to a research participant. In New Zealand, the Ethical Guidelines 
for Intervention Studies stipulate that:
212
 
Where findings obtained by an intervention study suggest serious disease, study 
participants who have not already given permission for the transfer of the 
information to their medical advisor should be urged to seek further advice and 
advised of any potential consequences of not seeking such advice. 
Furthermore, the American Society of Human Genetics and the Canadian College of 
Medical Geneticists both hold that the results of DNA analyses should be reported to an 
appropriate health professional who, in turn, has the responsibility of informing 
individuals of their presence and their meaning.
213
 In France, the National Consultative 
Ethics Committee for Health and Life Sciences recommends “the results of the tests be 
communicated in person by a physician whose competence permits a full explanation of 
the significance of the results.”
214
 In the UK, the Department of Health regulations do 
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not state how IFs are to be communicated, but the implication is that the participant’s 
GP should be involved.
215
 In Europe, the Additional Protocol to the Convention states 
that relevant IFs should be disclosed within a framework of healthcare or counselling, 
with an appropriate clinical professional supervising the research, but not explicitly 
disclosing any results themselves.
216
 Based on these authorities, it could be argued that 
the participant’s GP, or at the very least a doctor assigned to the research team is the 
appropriate person to disclose IFs .
217
 
Benefits of making GPs responsible for IF disclosures include the fact that GPs are 
likely to have more established relationships with their patients, and should therefore 
have a greater understanding of their individual needs.
218
 Consequently, in passing 
information onto a participant’s GP, researchers may feel that they have more 
adequately discharged any ethical obligation related to disclosure. This view is adopted 
by the ACMG who, in their aforementioned recommendations,
219
 provide that it is the 
research participant’s GP who will disclose the presence of an IF to the participant.
220
 
This is based on the belief that the GP will be able to contextualise any IFs for their 
patient in light of personal and family history, physical examination or other relevant 
findings.
221
 The ACMG’s rationale for placing responsibility for managing IFs with the 
GP reflects a wider understanding that the doctor-patient interaction is the appropriate 
place for such information to be explained and discussed.
222
 Lending further support to 
this argument, a study on expectations of participants in neuroimaging research found 
that a majority of research participants would prefer to learn about an IF from a doctor 
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on the research team, instead of the researcher themselves.
223
 Part of the motivation for 
this was that the participants wanted somebody who could answer their questions.
224
  
Nevertheless, there are still proponents of the view that, whenever IFs are to be 
disclosed, they should be disclosed directly to the research participant. These people 
believe that disclosure to the participant’s GP gives the research participant no control 
over the information and compromises their right to privacy.
225
 The GP is likely to 
record the information on the participant’s medical record before consulting with the 
participant, and it is argued that this chain of events is not consistent with respect for the 
research participant and their decisional autonomy.
226
 Proponents of this view believe 
that the research participant should control the information, and decide whom to 
consult.
227
 
In weighing these arguments, the author submits that there is a stronger basis for 
charging a participant’s GP with the responsibility of disclosing the presence of IFs. 
Consequently, research consent forms should ask for the contact information of a 
participant’s GP, so that, if necessary, they can be provided with information relating to 
IFs.
228
 In providing these contact details, a participant is impliedly authorising the 
disclosure of IFs to their GP. In many research settings it may, in fact, already be 
necessary to have a GP’s contact details, so researchers can advise the GP of their 
patient’s participation in the research. This approach may encounter difficulties where a 
participant is not registered with a particular GP, or medical centre. In such 
circumstances, a doctor assigned to the research team should be responsible for 
disclosure, with this approach communicated to the participant during the informed 
consent process. 
2 Rights of family members 
In general, health information should not be disclosed without the authorisation of the 
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individual concerned.
229
 However, if an IF will affect other people in a community, for 
example, biological family members, do they have a right to be informed? This is a 
privacy issue concerning the confidentiality of a research participant’s health 
information.
230
 In such situations, a conflict may arise between a participant’s right to 
privacy and the right of their family to know information that may also affect them.  
Several countries have issued guidelines to research and medical communities that 
recognise the utility of research results for family members. These guidelines often 
recommend providing results to relatives even when the information would otherwise be 
confidential.
231
 The Tri-Council Policy Statement (TCPS), which governs federally 
funded research in Canada, now recognises circumstances when the results of research 
can be disclosed to the family of a research participant. Although the TCPS provides 
that participants should be given the opportunity to decide whether family are informed 
of genetic information, it notes that preferences may be subject to overriding 
considerations that warrant disclosure of information to relatives in exceptional 
circumstances.
232
 A situation where genetic research reveals information about a serious 
or life-threatening condition that can be prevented or treated through intervention is one 
such circumstance.
233
 What amounts to a “serious or life-threatening” condition however 
is unclear.
234
 
Similarly in Australia, the National Statement on Ethical Conduct in Human Research 
permits disclosure to family without the participant’s consent only if “the research 
discloses that a family member may be at risk of a life-threatening or serious illness for 
which treatment is available or pending.”
235
 This permission comes with a caveat 
however; the participant’s consent must first be sought for the disclosure of the 
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information. Their refusal then authorises disclosure without consent in these limited 
circumstances. 
The UK takes a different approach when it comes to information uncovered in a research 
context. The Medical Research Council states only that “[p]articipants should be advised 
of the possible implications of genetic information for family members and the potential 
impact on family relationships.”
236
 The guidance therefore does not support researcher 
disclosure directly to participants’ families. This is a common position, but one that 
limits the avenues for discovery of information by potentially affected relatives.
237
 
New Zealand sets a comparatively high bar for the disclosure of health information to 
someone other than the person to which the information relates. Whilst the HIPC 
emphasises that, in general, health information should not be disclosed without the 
authorisation of the individual concerned, it is recognised that it may not always be 
possible or desirable to obtain individual consent.
238
 The HIPC provides an exception to 
the requirement of authorised disclosure in situations where:
239
  
(d) the disclosure of information is necessary to prevent or lessen a serious or 
imminent threat to –  
(iii) public health or public safety; or 
(iv) the life or health of the individual concerned or another individual. 
In order to disclose health information under this exception, a researcher needs to 
believe on reasonable grounds that it is not practicable or desirable to obtain individual 
authorisation, and that:
240
 
(1) there is a serious threat to public health, public safety or the life or health of an 
individual; 
(2) the threat is imminent; 
(3) the disclosure of the information would prevent or lessen that threat; and  
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(4) the disclosure of the information is necessary to prevent or lessen the threat. 
New Zealand law therefore permits the disclosure of IFs in situations where it is not 
practicable or desirable to gain an individual research participant’s consent to disclose IF 
information, but it is nevertheless deemed necessary, in order to, for example, prevent 
serious and imminent harm to the individual’s family. The HIPC provides that the 
disclosure must be made to a person who can do something to prevent or lessen the 
threat.
241
 Disclosing an IF to a family member would, in many situations, satisfy this 
requirement, as they are likely to be the individual whose life or health is imminently 
threatened and will be capable of acting to prevent or lessen the threat. The extent of 
disclosure is restricted to that necessary to prevent or lessen the threat.
242
 Researchers 
will therefore need to determine how much information needs to be disclosed to serve 
this purpose. 
There is, therefore, a growing consensus that where information is important for the 
health and wellbeing of relatives of participants and consent is not practicable or 
desirable, this information should be disclosed.
243
 The New Zealand law sets a high bar, 
and only permits disclosure in extreme circumstances, but does not require consent for 
disclosure to be first sought from the individual concerned. The author submits that the 
consent of a participant should, wherever possible, be sought before information relating 
to IFs is disclosed to family members. Only if seeking the individual’s consent is not 
possible, or they refuse to disclose the information themselves, should disclosure 
without consent be considered. 
3 IFs and Tikanga Māori  
Most discussions on the return of IFs to date have been based on the idea that genetic, 
brain and other physiologic and biologic data is personal property.
244
 Individual 
ownership of genes and human tissue is based on Western ideas of individualised 
property.
245
 Some communities, however, may not view genes as personal property, but 
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as cultural heritage
246
 or collective inheritance.
247
 This begs this question, how can 
researchers uphold Western ethical standards relating to individual medical information 
and simultaneously honour cultural values that may conflict with those standards?
248
  
As genetic research becomes more widespread, there is concurrent increasing demand to 
undertake genetic research on Māori.
249
 Māori are regarded by some in the research 
community as providing an ideal founder population, with well-described lineages and a 
high incidence of genetic diseases amenable to study.
250
 However genetic research is an 
area of prime sensitivity for Māori because of its association with whakapapa.
251
 Māori 
and other indigenous peoples generally consider body tissue to be tapu.
252
 Researchers 
undertaking medical research that involves the body, or any part of the body, such as 
organs, blood, hair, saliva, or other tissue, must therefore act in a respectful manner.  
The Guidelines for Researchers on Health Research Involving Māori were developed to 
assist research teams in developing research projects in a culturally appropriate way and 
in a way that is responsive to Māori.
253
 The Guidelines provide that research must be 
undertaken in a culturally sensitive and appropriate manner in full discussion and 
partnership with research participants.
254
 Moreover, the Guidelines state that informed 
consent should, in many cases, be gained from both individuals and representative 
organisations, for example whānau, hāpu or iwi.
255
  
Already established processes may aid researchers in the development of culturally 
appropriate policies for the return of IFs. There have been, for example, recent 
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incidences of Māori tribes modifying the clinical genetic service provided to them to 
make the process of receiving results from genetic testing more culturally appropriate.
256
 
Provisions have also been made so that Māori participants can have their extended 
family present when receiving results.
257
 Nevertheless, community consultation will 
continue to be important for the development of culturally appropriate research policies 
catered to individual studies.
258
 The development of these policies requires close 
cooperation between the research team and the whānau, as well as thorough consultation 
with the iwi to which the whānau belong.
259
 
Cultural considerations such as these are not restricted to research involving Māori. The 
issues raised are trans-cultural, and may arise in other communities, especially in the 
Pacific. Many New Zealand researchers will conduct research on participants with 
differing cultural values and backgrounds, and should therefore be open to developing 
culturally appropriate research protocols.  
C Wider Considerations 
The question of whether or not IFs should be disclosed to research participants also 
prompts consideration of a number of wider factors. These include the notion of a 
therapeutic misconception; the financial constraints facing researchers; and the potential 
for disclosure to harm research participants through, for example, discrimination, loss of 
health insurance, and emotional distress.  
1 Therapeutic Misconception 
While the primary goal of medicine is to treat individual patients, the primary goal of 
research is to produce generalisable knowledge.
260
 Nevertheless, many research 
participants suffer from what is called a therapeutic misconception, or the ‘mistaken 
conflating of medical research with clinical care’.
261
 As a consequence of information 
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conveyed during the informed consent process, research participants may overestimate 
the benefits of research by expecting that any anatomy imaged or genetics being studied 
are thereby being screened for clinical problems.
262
 Research participants may not 
appreciate that the MRI scans used to image their brain, for example, are not optimised 
for clinical diagnosis, because their purpose is for research.
263
 Participants in a genetic 
study may similarly not understand what genetic domains were not analysed as part of 
the research, and that the analytic tests used were not designed for clinical use.
264
  
Research participants often believe that researchers will provide treatment comparable to 
that provided by health professionals, and accordingly believe that researchers who come 
across information that can prevent future harm will disclose this information.
265
 
Furthermore, participants may misinterpret a researcher’s silence on the topic of clinical 
problems as a clean bill of health.
266
 Participants may consequently rely on researchers in 
ways that were never intended.
267
 It is important that it is made clear during the informed 
consent process that the purpose of medical research is to produce generalisable 
knowledge, and that as techniques used are not necessarily optimised for clinical 
diagnosis, researcher silence on the topic of clinical problems does not necessarily equate 
to a clean bill of health. 
2 Financial Constraints 
A further concern counselling against an obligation to return IFs is the burden that this 
obligation will place on the research enterprise. Returning IFs requires outlays of time 
and money that will need to be diverted from other research objectives.
268
 Investing this 
time and money into returning IFs, information that primarily benefits individual 
research participants, detracts from the aforementioned goal of creating generalisable 
knowledge. Some argue that such a diversion is not only financially unsustainable, but is 
also unethical.
269
 As one commentator admitted, “current procedures for handling 
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incidental findings may be adequate… because more stringent procedures would be 
difficult to implement in terms of both practicality and costs.”
270
 An associated 
consequence of requiring researchers to budget for managing IFs is: 
271
 
In the present financial climate…that half as much research gets done, and that has… 
a much greater impact on society and its health than the very low incidence of 
incidental findings which are actually correct, and the even lower incidence where 
there is something you could have done. 
To illustrate this point, if the recommendations put forward by the ACMG were 
adopted,
272
 the extra testing required would place an added burden on laboratories, and 
add significant costs to research reports.
273
 Furthermore, the lengthy list of mandatory 
gene tests, and the acknowledgement that it will continue to grow, suggests that pre and 
post-test counselling in order to adequately inform research participants would be 
extensive and costly.
274
 The financial constraints on research and research funding 
therefore counsel not only against an obligation to search for IFs, but also an obligation 
to return IFs. Money spent on disclosing IFs to individuals should, according to 
proponents of this view, be spent improving the health of society as a whole. 
3 Participant Harm 
Finally, disclosure of IFs will have implications not only on a participant’s health, but 
also on their employment, medical and life insurance and state of mind.
275
 In one 
illustration of this, a former teacher and soon to-be father volunteered for an MRI of his 
brain, which revealed a golf-ball sized tumour. The diagnosis came just before he 
applied for additional insurance for his family, which was subsequently denied as a 
result of the IF.
276
 In hindsight the participant believed he “should have thought about 
the consequences of volunteering more thoroughly.”
277
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The anxiety that knowledge of an IF may cause counsels against disclosure. 
Nevertheless it has been shown that professional concerns about anxiety outweigh 
public concerns.
278
 Whilst the public acknowledge the potential for IFs to induce 
anxiety, they maintain that it is the participant who should assess the impact for 
themselves.
279
 One respondent said:
280
  
I don’t want to live in the kind of society where the doctor tells me only what he 
thinks I should hear because I might be too sensitive. I need the facts. I have to be 
responsible for my health. 
Nevertheless, anxiety will be an inevitable consequence of disclosing IFs to research 
participants. In order to address the financial and psychological burdens that may come 
with IF disclosure, the potential for such consequences should form part of the 
discussion of risks and benefits during the informed consent process. Moreover, 
appropriate counselling should accompany sensitive disclosure in order to minimise 
anxiety. 
V How should Incidental Findings be managed in New Zealand? 
Following on from the above discussion, which has canvassed some of the most salient 
issues relating to IFs, this part formulates an approach to be employed by those involved 
in human subjects research in New Zealand. The current absence of a concrete 
framework not only unfairly burdens individual researchers and research teams with 
making judgment calls, but may also result in inconsistent and unethical management of 
findings.
281
 Findings of similar status should be managed consistently.
282
 Adopting an 
approach that facilitates the consistent application of policies thus promotes fairness and 
allows the rights and interests of research participants to be protected. 
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A The Approach 
Whilst some New Zealand research bodies, including the UAHPEC, require researchers 
to notify prospective research participants of the possibility of IFs during the informed 
consent process, there is currently no obligation to do so. Consequently, research 
participants are not receiving information that may play an important role in their ability 
to give informed consent and participate in research. In order for a person to consent to 
medical research, they must be fully informed.
283
 Research participants who are not 
advised of the possibility of IFs or the research team’s policy for IF management are not 
fully informed. The discovery of an IF can have a life-changing impact on an individual 
and their family, therefore, the risk of IFs is information that, to use the words of the 
Code of Rights, a reasonable consumer would expect to receive in order to make an 
informed choice.
284
 As informed consent for research procedures must be provided in 
writing,
285
 researchers should not only discuss these matters with participants, but also 
include them in the informed consent document. 
For a person to be fully informed and able to give their informed consent to participate 
in a research procedure, the information in the following sections should be discussed 
during the informed consent process. For a research proposal to gain ethics approval, 
ethics committees should ensure that this information will be provided to research 
participants. As these recommendations address information that a reasonable consumer 
would expect to receive, they arguably contain nothing that should not already be being 
discussed. It appears however, that in a majority of situations, this is not happening. In 
explicitly addressing this information, these recommendations promote responsible 
research conduct both by research teams and ethics committees. Whilst this may appear 
to be an overwhelming amount of information to be communicated to research 
participants, it is important to remember that the problem of IFs is by no means 
incidental. IFs, and the ways in which they are managed by researchers have life-
changing consequences, and therefore deserve significant attention. 
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1 The possibility of IFs 
The possibility of IFs should be disclosed both in consent forms and communications 
with potential research participants. It is not sufficient for researchers to address the 
possibility of IFs in their protocol, research design and communications with ethics 
committees; this information must also be communicated to participants during the 
informed consent process.  
It is at this stage that researchers should also emphasise the distinction between research 
and clinical care. This discussion will serve to dispel any therapeutic misconception that 
the prospective participant may possess. It should be explained that the purpose of the 
research is to produce generalisable knowledge, and not to make a clinical diagnosis of 
the individual’s underlying health conditions.
286
 Researchers should emphasise that 
although it is possible IFs will be uncovered, research procedures are not necessarily 
optimised for clinical diagnosis, and therefore an absence of IFs should not be taken to 
indicate a clean bill of health. 
With the recent release of the ACMG’s Recommendations for Reporting of Incidental 
Findings Clinical Exome and Genome Sequencing, the issue of whether a researcher has 
a duty to seek, detect and report IFs has become topical.
287
 The author proposes that the 
adoption of such an approach would be unnecessarily burdensome on researchers. It is 
therefore undesirable to place on researchers an affirmative duty to seek, detect and 
report IFs. Participants should be advised that researchers will not search for IFs. 
2 Examples of IFs a research procedure may yield 
When designing their studies, researchers should, to the greatest extent possible, 
identify any IFs that may reasonably result from the research procedure. During the 
informed consent process, researchers should provide participants with this 
information.
288
 It may be reasonably foreseeable, for example, that research involving 
MRI may indicate the presence of a suspicious mass. Participants should, therefore, be 
warned of this possibility. Nevertheless, it is impossible to anticipate everything that 
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might be discovered. A researcher would only be expected to advise of IFs that are 
reasonably foreseeable.  
3 IF disclosure and management plan 
Researchers should responsibly address IFs in the event that they arise. In order to do so, 
each research team should be develop a pathway for IF management. This pathway 
should be explained to prospective research participants during the informed consent 
process. 
This discussion should include an explanation of the researcher’s policy on IFs that will 
and will not be disclosed to the research participant. It should be explained that IFs 
range along a spectrum of severity, with only certain findings serious enough to warrant 
default disclosure. IFs should meet three key criteria before they will be disclosed to 
participants:  
(1) the findings are scientifically confirmed;  
(2) the findings have serious or life-threatening health implications for the 
participant; and  
(3) a course of action to ameliorate or treat the condition is readily 
available.  
These criteria roughly accord with the strong net benefit criteria discussed in Part IV. 
Setting the threshold for default disclosure at this level has the effect of minimising 
unnecessary anxiety that may result from informing a participant of a condition they can 
do nothing about, or one that will not have serious health implications. 
Although it is desirable to set the bar for default disclosure at this level, participants 
should, in line with respect for personal autonomy, be able to assert a preference for 
greater or lesser disclosure. Participants should be informed that they have a right to 
know or not to know information about themselves, and may therefore waive or request 
disclosure of certain categories of information. It may understandably be the case that, 
even though there may be no treatment currently available, a participant nevertheless 
wishes to be informed of an IF indicating susceptibility to a disease such as 
Alzheimer’s. Researchers should respect the wishes expressed by participants unless 
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failing to disclose an IF would be immediately life threatening or comparably dangerous 
to the participant or a third party. Participants should be informed that this is the 
approach the research team will adopt. A residual ability to override the wishes of a 
research participant is important, as it recognises that the consequences of IFs are not 
necessarily restricted to the individual participant. In situations where the individual or a 
family member is at risk of life-threatening harm, a researcher should override the 
wishes of the participant and disclose the presence of the IF. 
Wherever possible, however, the consent of a participant should be sought before 
information relating to IFs is disclosed to third parties. As was discussed in Part IV, 
there is a growing consensus that where information is important for the health and 
wellbeing of relatives of participants and consent is not practicable or desirable, this 
information should be disclosed.
289
 The approach currently taken in New Zealand sets a 
high bar, and only permits disclosure in extreme circumstances. Whilst the threshold is 
set sufficiently high, an individual should, wherever possible, be given the opportunity 
to disclose this information to their relatives. Only if seeking the individual’s consent is 
not possible, or they refuse to disclose the information themselves, should disclosure 
without consent be considered.  
As a participant is likely to share a more established relationship with their GP than the 
research team, a participant’s GP is the appropriate person to disclose the presence of an 
IF. Consequently, participants should be required to provide the name and contact 
details of their GP on the informed consent document. The participant should be advised 
that their GP will assume responsibility for IF disclosure. Requiring a participant to 
provide the contact details for their GP means that those who participate in the research 
have consented to their GP being contacted in the event of IF discovery. As a result, 
issues relating to privacy and the disclosure of health information under the HIPC are 
not invoked, as, under r 11, the participant has authorised disclosure. Any prospective 
participant who does not have a regular GP or is not enrolled at a medical centre should 
be advised that a doctor assigned to the research team will instead be responsible for IF 
disclosure. 
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4 Risks and benefits associated with IF disclosure 
Researchers should address the risks and benefits associated with IF disclosure during 
the informed consent process. In particular, harms such as the impact on a participant’s 
insurability or employment and the potential for anxiety should be addressed. Potential 
benefits including the correlation between early detection and positive outcomes should 
also be discussed. 
In order to adequately inform participants of the risk to one’s insurability, informed 
consent documents should include a passage along the following lines:
290
 
If the researchers find an IF, this might affect your insurability. Applicants for 
insurance are required to disclose all facts within their knowledge that might 
affect a reasonable insurer’s decisions about whether to provide insurance or what 
premiums to charge for insurance. If you apply for insurance or for reinstatement 
of insurance before an IF has been investigated and any problem ruled out, or if 
an IF turns out to reveal a condition or abnormality, you may not be able to get 
insurance or you may only be able to get insurance at a higher price that if you 
didn't know about the IF. If you do not disclose IFs, your insurance contract may 
be voidable by the insurance company. 
Inclusion of such a text will contribute to a better understanding by potential 
participants of the insurability risks and other potential harms associated with 
participating in the research.
291
 
Information relating to the risks and benefits of IF disclosure may be material to an 
individual’s decision whether or not to participate in the research. Some participants 
may choose not to participate in such circumstances. That is their right. Others will be 
concerned about the potential effects of learning this information, such as whether it 
might impact on their ability to obtain insurance or participate in certain activities.
292
 It 
is therefore important that individuals are aware of these risks and can take them into 
consideration when deciding whether to participate. 
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5 Capacity for collective decision-making 
The Guidelines for Researchers on Health Research Involving Māori assist research 
teams in developing their projects in a culturally appropriate way. The Guidelines do 
this by emphasising the importance of the principles such as partnership, and by 
suggesting ways that research can be structured to ensure it is undertaken in a culturally 
sensitive and appropriate manner. The Guidelines provide that informed consent should, 
in many cases, be gained from both individuals and representative organisations, for 
example whānau, hāpu or iwi.
293
 However the concept of collective decision-making is 
not exclusive to Māori culture. Consequently, research teams should be prepared to 
structure their processes in a way that ensures those involved in collective decision-
making are adequately informed. The research team should also demonstrate respect for 
cultural heritage and cultural practises including collective decision-making.  
Many New Zealand researchers will conduct research on participants with differing 
cultural values, and should be open to developing culturally appropriate research 
protocols. Consequently, the ideas put forward in the Guidelines for Researchers on 
Health Research Involving Māori should be broadened to apply in a variety of cultural 
contexts. Where a research participant wishes to receive disclosure of an IF in the 
presence of family, this should be facilitated. Moreover, where a community places 
importance on collective consent for a particular procedure, for example, genetics 
research, researchers should be open to this. It is nevertheless still important to ensure 
that an individual’s rights and interests are being adequately protected, but in many 
circumstances this will be able to occur in the context of wider community engagement. 
B Implementing the Approach 
In implementing the recommendations detailed above, research teams and ethics 
committees will play an important role in improving participant awareness about the 
realities of IFs. The recommendations undoubtedly involve a considerable assumption of 
responsibility by both groups. At the same time however, these recommendations 
release some of the current pressure on research teams to make life-changing judgment 
calls. With the implementation of these recommendations, both researchers and 
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participants will be better informed. IF disclosure will be based on reasoned judgment 
generated from the preferences of informed participants.  
For the recommendations to achieve this desired effect however, they should be formally 
incorporated into the existing human subjects research framework. As was addressed in 
Part III, the current framework governing human subjects research in New Zealand is 
inadequate in the guidance it provides on IFs. 
1 National Ethics Advisory Committee Guidelines 
Researchers should be shouldering positive duties in relation to IFs. In order to reflect 
this, the NEAC’s Ethical Guidelines for Intervention Studies and Ethical Guidelines for 
Observational Studies should each include a section detailing the information that 
researchers are required to discuss with prospective participants during the informed 
consent process. This will include the information relating to IFs set out in the 
recommendations at sub-part A. The Guidelines are an appropriate mechanism through 
which to implement these recommendations, as their stated aim is to contribute to better 
health outcomes in New Zealand by assisting researchers to perform sound studies.
294
By 
including a section that details the information to be discussed relating to IFs, this 
objective will be enhanced. Researchers will receive increased guidance and 
participants, more relevant information, thereby improving the quality of the study 
overall. Importantly, these guidelines constitute ethical standards under right 4(2) the 
Code of Rights. Any failure by researchers to observe them is considered a breach of the 
Code of Rights. What will happen in the event of a breach, however, is beyond the 
scope of this paper. 
2 Code of Health and Disability Services Consumers’ Rights 
The duties on researchers to inform participants about IFs should also be reflected 
explicitly in the Code of Rights. It has been argued that under the current Code of Rights 
provisions, information relating to IFs could be considered as part of the risks and 
benefits of a procedure.
295
 In recognition of the serious implications IFs can have, 
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however, they should be addressed explicitly. To facilitate this, a further subsection 
should be included in right 6 of the Code of Rights, providing that: 
(1) Every consumer has the right to information that a reasonable 
consumer, in that consumer’s circumstances would expect to receive, 
including –  
…   
(h) In the case of research, the possibility of incidental findings, and an 
explanation how such findings will be managed. 
The inclusion of this provision should help ensure that both research participants and 
researchers are more aware of a participant’s right to be informed of IFs as well as the 
corresponding duty on the researchers to disclose this information. Nevertheless, this 
inclusion should not detract from a researcher’s need to refer to the NEAC Guidelines 
for guidance on the extent of this duty. 
3 Ethics Committees 
Finally, individual ethics committees, such as the UAHPEC, should include the 
recommendations relating to IFs detailed in sub-part A in their ethics approval 
requirements. In this way, ethics committees also assume responsibility for ensuring 
that researchers are providing adequate information to participants. As the extent of 
obligations on researchers becomes more familiar and entrenched, it may not be 
necessary to provide such explicit guidance, however until that point, ethics committees 
should play their role in facilitating the consistent and comprehensive dissemination of 
this information. 
VI  Conclusion 
To date, the issue of IFs in research has been poorly recognised and seldom discussed. 
Current guidance relating to the management of IFs both in New Zealand and overseas 
is inconsistent, limited, and does not adequately address the rights of research 
participants. Further compounding this problem, the rapid development of technology 
serving the health sector, means that the likelihood of discovering IFs has increased 
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dramatically. Consequently, a framework for the management of such findings is 
urgently required. This framework will facilitate the greater dissemination of 
information to research participants. During the informed consent process, potential 
research participants should be informed of the possibility of IFs, as well as 
arrangements for IF management. This framework should be implemented through a 
combination of amendments to pre-existing guidelines, the Code of Rights and 
individual ethics committee protocols.  
The problem of IFs is important and deserves broad discussion among researchers, 
research participants, ethics committees, funders and oversight bodies. Handling IFs 
responsibly requires attention to the ethical duties of researchers when faced 
unexpectedly with information that could save a life, significantly alter clinical care, or 
prove important to the research participant.
296
 Current piecemeal approaches fail to 
ensure that all research participants are adequately informed about IFs. Accordingly, this 
paper advocates adoption of an approach that makes it clear to participants what IFs are, 
which IFs will be returned to them and when this will occur. This approach strikes an 
appropriate balance, giving deference to a researcher’s considered judgment about the 
best approach to returning IFs given the particular circumstances of a research protocol, 
while allowing participants to know from the outset how IFs will be managed. IFs may 
seem, at first glance, to be a minor or peripheral concern. Upon closer scrutiny, however, 
IFs are anything but incidental. It is therefore imperative that as technology develops, 
the law is able to adequately protect the interests of research participants, and establish 
clear expectations of researchers. 
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